Gilead Sciences, Inc. GILD announced that it will acquire clinical-stage biopharmaceutical company, CymaBay Therapeutics, Inc. CBAY, for $32.50 per share in cash or a total equity value of $4.3 ...

CBaySystems is a leading provider of technology-enabled clinical documentation services company. CBay serves healthcare providers with a broad range of solutions including voice capture, speech ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

And CBAY stock investors are closely watching. CBAY Stock: 2024 Could Be A Game-Changer CymaBay has had a really good year. In November, the company's drug, called seladelpar, emerged as the ...